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Abstract  29 
Objective: Platinum-based chemotherapy (PBC) is the most effective cytotoxic treatment for 30 
advanced adrenocortical carcinoma (ACC). Excision repair cross complementing group 1 (ERCC1) 31 
plays a critical role in the repair of platinum-induced DNA damage. Two studies investigating the role 32 
of ERCC1 immunostaining as a predictive marker for the response to PBC in ACC had reported 33 
conflicting results. Both studies used the ERCC1-antibody clone 8F1 that later turned out to be not 34 
specific. The aim of this study was to evaluate the predictive role of ERCC1 with the new specific 35 
antibody in a larger series of ACC.  36 
Design and Methods: 146 ACC patients with available FFPE slides were investigated. All patients 37 
underwent PBC (median cycles=6), including cisplatin (n=131) or carboplatin (n=15), in most cases 38 
combined with etoposide (n=144), doxorubicin (n=131) and mitotane (n=131). Immunostaining was 39 
performed with the novel ERCC1-antibody clone 4F9. The relationship between ERCC1 expression 40 
and clinico-pathological parameters, as well as best objective response to therapy and progression-free 41 
survival (PFS) during PBC was evaluated.  42 
Results: High ERCC1 expression was observed in 66% of ACC samples. During PBC, 43 patients 43 
experienced objective response (29.5%), 49 stable disease (33.6%), 8 mixed response (5.5%) and 46 44 
progressive disease (31,5%) without any relationship with the ERCC1 immunostaining. No significant 45 
correlation was also found between ERCC1 expression and progression-free survival (median 6.5 vs 6 46 
months, P=0.33, HR=1.23, 95%CI=0.82-2.0). 47 
Conclusion: ERCC1 expression is not directly associated with sensitivity to PBC in ACC. Thus, other 48 
predictive biomarkers are required to support treatment decisions in patients with ACC. 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
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Introduction 57 
Platinum-based chemotherapy (PBC) is the most effective cytotoxic treatment for advanced 58 
adrenocortical carcinoma (ACC), mostly in combination with etoposide and doxorubicin plus mitotane 59 
in the EDP-M regime1. However, the best objective response rates remain below 30% and the impact 60 
on overall survival is not satisfying as shown in the phase III clinical trial FIRM-ACT 2. Similarly, 61 
other possible cytotoxic drugs such as streptozotocin2 or gemcitabine did not show a better 62 
effectiveness3 and no effective targeted therapies have emerged for ACC patients with advanced 63 
disease4-6. Finally, PBC as other chemotherapeutic combinations is associated with relevant toxicity. 64 
Thus, it is obvious that there is an urgent need of biomarkers that may serve to predict the response to 65 
PBC. 66 
Excision repair cross complementing group 1 (ERCC1) is an important member of the nucleoside 67 
excision repair pathway, which plays a critical role in the DNA repair by removing DNA covalent 68 
helix-distorting adducts caused by platinum compounds7. ERCC1 has been demonstrated to be a 69 
predictive biomarker for platinum treatment in several cancers, such as non-small cell lung cancer, 70 
testicular germ cell tumor, bladder cancer, pancreatic carcinoma and gastric cancer8-12. Two previous 71 
studies, one from our group13 and one from France14 investigated ERCC1 immunostaining in 72 
relationship with the response to PBC in a relatively small series of ACC patients (n=45 and n=33, 73 
respectively). These two studies described a similar overall response rate to PBC (25-30% of cases), 74 
but reported conflicting results regarding the influence of ERCC1 on sensitivity to PBC, being 75 
significant only in the first study. All the previous studies on ERCC1 immunostaining, including those 76 
on ACC, have been performed by using the monoclonal anti-mouse antibody clone 8F1. However, 77 
already some years ago, it had been suggested that this clone might be not specific, being ERCC1 not 78 
the principal antigen recognized by the 8F1 antibody15, 16. In fact, more recently, it has been 79 
demonstrated that the clone 8F1 immunoglobulin recognizes also the choline phosphate 80 
cytidyltransferase 1 alfa (PCYT1A), an unrelated nuclear membrane protein, involved in the 81 
metabolism of phosphatidylcholine biosynthesis17. These findings raise doubts on previously 82 
published data using the clone 8F1 to investigate ERCC1 as a predictive marker to PBC in several 83 
solid tumors. Finally, a new highly specific clone 4F9 has been identified and then validated 17-19. 84 
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Thus, the aim of the present study was to evaluate ERCC1 immunostaining with the new highly 85 
specific clone 4F917, 18 in a larger series of ACC and to correlate it with the response to PBC. 86 
 87 
Subjects and methods 88 
Patients and treatment regimen 89 
Inclusion criteria were age of at least 18 years, histopathologic diagnosis of ACC, available formalin-90 
fixed paraffin embedded (FFPE) specimens and treatment with PBC. We identified a total of 153 91 
patients that fulfilled these criteria and were treated with PBC in our centers between 2004 and 2015. 92 
Seven of these patients received only one cycle of PBC and were then excluded from further analysis. 93 
Thus, the final series included 146 patients with advanced ACC (F:M=90:56, median age 48 years). 94 
None of these patients were already included in our previous paper on ERCC113, while 49 participated 95 
in the FIRM-ACT study2. Specifically, 127 samples derived from primary surgery, 6 from local 96 
recurrences, 4 from biopsies (patients not operable) and 9 from distant metastasis. The baseline 97 
clinical parameters, such as sex, age at initial diagnosis, tumor size, biochemical evaluation, tumor 98 
stage according to the European Network for the Study of Adrenal Tumors (ENSAT) classification20, 99 
Weiss score, Ki67 proliferation index, presence and number of distant metastases, and previous local 100 
and/or pharmacological treatments are given in Table 1. All baseline data were collected through the 101 
ENSAT Registry (www.ens@t.org/registry). 102 
The treatment regimen included cisplatin (n=131) or carboplatin (n=15) and was in most cases 103 
administered as combination therapy (see details Table 1). The median number of PBC cycles was 6 104 
ranging from 2 to 15. Treatment was discontinued in cases of unacceptable toxicity, patient’s refusal 105 
or evidence of disease progression. A total of 131 patients (90% of cases) were treated with 106 
concomitant mitotane (target plasma concentration: 14-20 mg/L). 114 patients received PBC as first-107 
line cytotoxic treatment (78% of cases), while the remaining 32 patients were treated with PBC as 108 
second- or third- line therapy, with a history of failed streptozotocin2 or gemcitabine + capecitabine3 109 
(Table 1). All patients had undergone regular and standard follow-up visits with clinical, biochemical, 110 
and radiological (abdominal and thoracic CT scan with contrast agent) evaluation with a staging 111 
interval usually every 8 weeks. The sensitivity to PBC was evaluated as progression-free survival 112 
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during treatment and as best overall objective response. For this evaluation, according to our clinical 113 
practice, all radiological images were reviewed by the local expert radiologists and discussed in our 114 
multidisciplinary tumor board meetings to determine a final consensus response (progressive disease, 115 
stable disease, partial or complete response). Clinical benefit was defined as stable disease or 116 
treatment response for a minimum of 4 months.  117 
The collection of the clinical data and the biomaterial for this retrospective study was approved by the 118 
ethics committee of the University of Wuerzburg (No. 93/02 and 88/11) according to the Declaration 119 
of Helsinki. Written informed consent was obtained from all patients. 120 
 121 
Immunohistochemistry 122 
A total of 146 FFPE adrenocortical tissues on standard full slides were evaluated by 123 
immunohistochemistry. In brief, sections were deparaffinized and immunohistochemical detection was 124 
performed using an indirect immunoperoxidase technique after high temperature antigen retrieval in 125 
10 mM citric acid monohydrate buffer (pH 6.5) in a pressure cooker for 13 min. Blocking of 126 
unspecific protein-antibody interactions was performed with 20% human AB serum in PBS for 1h at 127 
room temperature. Primary antibody for ERCC1 was the new highly specific monoclonal anti-mouse 128 
antibody (mAb) clone 4F9 (UM500008, dilution 1:100) that was purchased from OriGene 129 
Technologies, Inc (Rockville, USA). A mouse negative control was used (Dako North America Inc., 130 
Carpinteria, USA). The slices were incubated overnight at 4°C. Signal amplification was achieved 131 
with En-Vision System Labeled Polymer-HRP Anti-Mouse (Dako) for 40 min and developed for 10 132 
min with DAB Substrate Kit (Vector Laboratories, Burlingame, CA) according to the manufacturer’s 133 
instructions. Nuclei were counterstained with Mayer’s hematoxilin for 2 min. For positive controls, 134 
sections of colon adenocarcinoma, renal cell carcinoma, breast cancer, hepatocellular carcinoma and 135 
normal tonsil were chosen, while cells of the tumor stroma served as internal negative control.  136 
All slides were analyzed independently by two investigators blinded to clinical information (V.L. and 137 
S.S.) Nuclear staining intensity was graded as negative (0), low (1), medium (2), or strong (3). The 138 
percentage of tumor cells with positive nuclei was calculated for each specimen and scored 0 if 0% 139 
were positive, 0.1 if 1–9% were positive, 0.5 if 10–49% were positive and 1 if 50% or more were 140 
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positive. A semiquantitative H-score was then calculated by multiplying the staining intensity grading 141 
score with the proportion score as described previously 13. In case of discrepant results, staining 142 
intensities were jointly assessed by both investigators, forming the final score by consensus. Inter-143 
observer agreement was investigated via Pearson’s correlation coefficients 0.72 (95%CI: 0.63-0.79). 144 
 145 
Comparison between anti-ERCC1 antibody clone 8F1 vs clone 4F9 146 
We also intended to re-evaluate our old results obtained with the mAb against ERCC1 clone 8F1 (old 147 
batch)13 with the new high specific mAb clone 4F9. To this aim, we re-stained 38 ACC samples out of 148 
the 45 previously published and re-investigated the relationship between ERCC1 expression and the 149 
response to PBC in terms of both progression-free survival (PFS) and disease-specific survival (DSS) 150 
after treatment. Moreover, the specificity of the currently available clone 8F1 has been shown to be 151 
altered from the old clone 8F121, 22. In addition, we also evaluated a subgroup of 21 out of the 146 152 
samples in our present series with the current clone 8F1 (new batch) in addition to the new clone 4F9.  153 
 154 
Statistical analysis 155 
The Fisher’s exact or the Chi-square tests were used to investigate dichotomic variables, while 156 
continuous variables were investigated with a two-sided t test (or non-parametric test). A non-157 
parametric Kruskal-Wallis test, followed by Dunn’s test, was used for comparison among several 158 
groups for non-normal distributed variables. Correlations and 95% confidence intervals (95%CI) 159 
between different parameters were evaluated by linear regression analysis. PFS was defined as the 160 
time from the date of first administration of PBC to the first radiological evidence of disease 161 
progression or death, as appropriate. DSS was defined as the time from the first administration of PBC 162 
to disease-specific death or last follow-up. All survival curves were obtained with Kaplan-Meier 163 
estimates, and the differences between survival curves were assessed by the log-rank (Mantel-Cox) 164 
test. For the calculation of hazard ratios (HR), two ACC-groups with low or high protein expression 165 
were considered (high expression: H-score ≥2). A multivariate regression analysis was performed via 166 
a Cox proportional hazard regression model, aiming to identify factors that might independently 167 
influence survival. Statistical analyses were made using GraphPad Prism (version 6.0, La Jolla, CA, 168 
7 
 
USA) and SPSS Software (PASW Version 21.0, SPSS Inc., Chicago, IL, USA). P values <0.05 were 169 
considered as statistically significant.  170 
 171 
Results 172 
Efficacy of platinum-based chemotherapy  173 
The data about efficacy of PBC in the current series of 146 patients with advanced ACC are 174 
summarized in Table 2. Concerning the best objective response during PBC, one patient experienced 175 
complete response (0.7%) and 42 patients partial remission (28.8%), 49 stable disease (33.5%), 8 176 
mixed response (5.5%) and 46 progressive disease (31.5%), respectively. The median PFS during PBC 177 
was 6 months, ranging from 2 to 18, while the median DSS was 17 months, ranging from 1.5 to 127. 178 
Additionally, we observed a clinical benefit defined as at least a stable disease for a minimum of 4 179 
months in 84 patients (58%) with a median PFS in this group of 6 months (range: 4-18). Only one 180 
patient died unrelated to ACC during follow up. Thus, overall survival was more or less identical to 181 
DSS (data not shown). 182 
 183 
ERCC1 expression and baseline clinical characteristics in ACC 184 
Nuclear ERCC1 immunostaining was homogeneous in individual ACC samples with a median 185 
percentage of positive cells of 80% (> 50% in 135/146 samples, 92.5%). Tissue samples exemplifying 186 
the range of staining intensity are shown in the Figure 1. ERCC1 expression was low (H-score 0-1) in 187 
50 samples (34.2% of cases) and high (H-score 2-3) in 96 samples (65.7%). We did not observe any 188 
significant differences in ERCC1 immunostaining among primary tumors, local recurrences and/or 189 
distant metastasis. No significant correlation was also observed between the nuclear ERCC1 190 
expression and the ENSAT tumor stage at the time of diagnosis, the Weiss score or the Ki67 191 
proliferation index.  192 
 193 
Predictive role of ERCC1 expression on sensitivity to platinum-based chemotherapy 194 
Considering the potential predictive role of ERCC1 immunostaining on the objective response to PBC, 195 
no significant differences were observed between the groups with high and low nuclear ERCC1 196 
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expression (Table 2). Similarly, no differences were found in terms of both PFS (median 6.5 vs 6 197 
months, respectively, P=0.33, HR=1.23, 95%CI=0.82-2.0) and DSS (median 17 vs 16.5 months, 198 
respectively, P=0.87, HR=1.03, 95%CI=0.70-1.53) (Figure 2A-B). 199 
 200 
Comparison between anti-ERCC1 antibody clone 8F1 vs clone 4F9 201 
We re-stained 38 out of 45 ACC samples of our previously published series (stained with the 8F1 202 
clone old batch) with the new clone 4F9. Not unexpected, ERCC1 expression in terms of H-score 203 
corresponded in only 49% of cases. As a consequence, ERCC1 nuclear expression did not longer 204 
significantly correlate with response to PBC in terms of both PFS (data not shown) and DSS 205 
(Supplementary Figure 1A and B). 206 
Furthermore, we stained 21 out of the present 146 samples with the currently available clone 8F1 (new 207 
batch) additionally to the clone 4F9. Two representative examples are shown in the Supplementary 208 
Figure 2. Comparing the ERCC1 immunostaining results we observed here a correspondence between 209 
the two antibodies in 81% of cases.   210 
 211 
Discussion 212 
We evaluated the potential role of ERCC1 nuclear expression as predictive biomarker to PBC in the 213 
largest series of ACC patients up to date (n=146) by using for the first time the new high ERCC1-214 
specific monoclonal antibody clone 4F9. To note, ERCC1 has been previously demonstrated to be a 215 
predictive biomarker for platinum treatment in several cancers, such as non-small cell lung cancer 216 
(NSCLC), testicular germ cell tumors, bladder cancer, pancreatic carcinoma and gastric cancer8-12. In 217 
ACC, we previously demonstrated in a relatively small series of patients that ERCC1 immunostaining 218 
was significantly correlated with overall survival during PBC13. Another study, however, did not 219 
confirm this finding14. Nevertheless, several concerns about the reliability of the ERCC1 220 
immunohistochemical analysis have been raised recently. First, it has been demonstrated that the clone 221 
8F1 used in all the reported studies is not specific for ERCC115-17. Specifically, the anti-ERCC1 222 
antibody clone 8F1 has been identified to stain also the PCYT1A, a phospholipid synthesis enzyme 223 
regulated by RAS17, 23 with no known clinical implication in platinum drug resistance. PCYT1A has 224 
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also been confirmed to play a role as prognostic biomarker in both lung and head and neck squamous 225 
cell carcinomas23. 226 
Moreover, the batch of the clone 8F1 in use since 2011 seems not to be identical with the batch in use 227 
in 200619, thus rendering new data about NSCLC not comparable with previous ones22. According to 228 
this new information, important previous results on the role of ERCC1 in the treatment of NSCLC 8 229 
have been revised by the same group21. Furthermore, this year the first randomized trial to evaluate 230 
ERCC1 prospectively in 648 patients with NSCLC (ET trial) has been published definitively 231 
demonstrating that selecting chemotherapy using the commercially available ERCC1 antibodies (clone 232 
8F1) does not confer any additional survival benefit24.  233 
In parallel, a new highly ERCC1-specific clone 4F9 has been recently proposed and validated 17-19. For 234 
all these reasons, we decided to use the clone 4F9 to investigate a new large series of ACC samples in 235 
order to re-evaluate our previous results on ERCC1 as predictive marker of sensitivity to PBC. Most 236 
importantly, we could not confirm the previous results and our data now indicate that ERCC1 itself is 237 
probably not the main factor involved in the response to PBC in ACC patients. In addition, we were 238 
able to demonstrate that the current version of the clone 8F1 significantly differs from the old one that 239 
we used for our pilot study13 and we were not able to reproduce the earlier results using now the same 240 
tumor samples. 241 
One reason that could explain the lack of correlation between ERCC1 and PBC, independently from 242 
the issues with immunohistochemistry, is that ERCC1 works together with the XPF protein, codified 243 
by ERCC4. ERCC1–XPF complex is a two subunit structure-specific endonuclease that plays a key 244 
role during the nucleotide excision repair (NER) process7, 25. Thus, XPF itself might be involved in the 245 
sensitivity to the response to PBC26, 27. However, the ET trial demonstrated that XPF expression is not 246 
predictive for response to 648 patients with NSCLC24. Moreover, the ERCC1–XPF complex makes 247 
incisions on the damaged DNA strand on the 5′ side and acts in cooperation with several other 248 
proteins, like XPC–RAD23B, XPA, RPA, TFIIH and XPG, during the NER process28, 29. Thus, 249 
although ERCC1 plays a major role in the NER, several other proteins and mechanisms could 250 
influence the response to PBC.  251 
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Another explanation, why ERCC1 expression and clinical outcome in our and other series did not 252 
correlate could be the fact that virtually all patients have received in parallel to the platinum derivate 253 
1-3 other additional cytotoxic drugs (mostly doxorubicin, etoposide and mitotane) diluting the 254 
hypothesized correlation. Other potential biomarker could for instance be involved in the prediction of 255 
response to these concomitant treatments (i.e. TOP2A30). Finally, one potential limitation in our study 256 
as well as in several others might be that ERCC1 was assessed on tumor specimens obtained months 257 
or even years before the start of chemotherapy. Nevertheless, we did not observe any significant 258 
differences in ERCC1 immunostaining among primary tumors, local recurrences and/or distant 259 
metastasis, thus suggesting that the ERCC1 levels remain quite stable over the time and tumor 260 
progression. 261 
More generally, the search for predictive biomarkers to conventional cytotoxic chemotherapy has been 262 
proven challenging due to frequent discrepant and non-replicable findings. And this is true not only for 263 
protein expression where issues with antibodies and immunohistochemical analysis are common, but 264 
also for gene expression. Thus, if a plethora of biomarkers predicting chemotherapy efficacy have 265 
been evaluated also in the clinical setting, none of them is ready for clinical implementation yet31. 266 
Considering that most mechanisms of resistance or sensitivity to chemotherapy are multifactorial, a 267 
combinatorial approach and further efforts are required32. 268 
Concerning the response rate to PBC in general, we observed an objective partial response in 29.5% of 269 
cases and a stable disease in further 33.5%, thus confirming that PBC is the currently most effective 270 
cytotoxic therapy for advanced ACC. These data are generally superimposable to those reported in the 271 
FIRM-ACT study on EDP-M2.  272 
In conclusion, ERCC1 expression as detected by immunostaining is not directly associated with 273 
sensitivity to PBC in ACC. Thus, the search for predictive biomarkers in this devastating disease with 274 
poor response to medical therapy has to continue.  275 
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Figure legends 419 
 420 
Figure 1. Representative examples of nuclear ERCC1 immunostaining in adrenocortical tissue 421 
samples using the monoclonal ERCC1 antibody clone 4F9. A) Normal adrenal gland; B) 422 
Adrenocortical carcinoma with high intensity and high percentage of positive cells (H-score 3). C) 423 
Adrenocortical carcinoma with intermediate intensity and high percentage of positive cells (H-score 424 
2). D) Adrenocortical carcinoma with low intensity and low percentage of positive cells (H-score 0,5). 425 
Magnification 1x10. 426 
 427 
Figure 2. Relationship between ERCC1 expression and response to platinum-based 428 
chemotherapy in 146 patients with adrenocortical carcinoma (ACC). Progression-free survival 429 
(A) and overall survival (B) during treatment (Kaplan-Meyer curves and log-rank test) in ACC 430 
patients with high (H-score ≥2) and low staining (H-score ≤1) of ERCC1.  431 
432 
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Supplementary data 433 
 434 
Supplementary Figure 1. Re-evaluation of the overall survival in the old series of 38 patients 435 
with adrenocortical carcinoma treated with platinum-based chemotherapy 13. (A) ERCC1 436 
immunostaining with the 8F1 clone (old batch) (B) ERCC1 immunostaining with the new specific 4F9 437 
clone. 438 
 439 
Supplementary Figure 2. Direct comparison between ERCC1 antibodies 4F9 (A) and C) and 8F1 440 
clone (new batch) (B) and D)) in one normal adrenal gland (A) and B)) and in one adrenocortical 441 
carcinoma (C) and D)).  Magnification 1x20. 442 
 443 
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